Cullinan Oncology Completes $98.5 Million Series B Financing

Jun 4, 2020 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing …

CouponFollow Extension

$98
OFF

Cullinan Oncology Completes $98.5 Million Series B Financing

4 weeks from now

Jun 4, 2020 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing …

businesswire.com

$98
OFF

Cullinan Oncology Completes $98.5 Mln Series B Financing

4 weeks from now

Jun 4, 2020 · Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv

reuters.com

$98
OFF

Cullinan Oncology Closes $98.5M Series B Financing Round

4 weeks from now

Jun 4, 2020 · Cullinan Oncology, a Cambridge, Mass.-based oncology research company, closed a $98.5m Series B financing FinSMEs The Website About Venture Capital News . FinSMEs …

finsmes.com

$98
OFF

Cullinan Oncology Completes $98.5 Mln Series B Financing

4 weeks from now

June 4 (Reuters) - Cullinan Oncology: Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv

reuters.com

$98
OFF

Series B - Cullinan Therapeutics - 2020-06-04 - Crunchbase

4 weeks from now

Cullinan — Cullinan Oncology Completes $98.5 Million Series B Financing News • Jun 4, 2020 vcaonline — Cullinan Oncology Completes $98.5 Million Series B Financing Jon Wigginton, …

crunchbase.com

$98
OFF

Cullinan Oncology Completes $98.5 Million Series B Financing

4 weeks from now

Jun 4, 2020 · Jon Wigginton, M.D. Joins as Chief Medical Officer Jennifer Michaelson, Ph.D. Promoted to Chief Development Officer, Biologics CAMBRIDGE, Mass.--(BUSINESS...

streetinsider.com

$98
OFF

Cullinan Oncology Completes $98.5 Million Series B Financing

4 weeks from now

Jun 4, 2020 · Jon Wigginton, M.D. Joins as Chief Medical Officer Jennifer Michaelson, Ph.D. Promoted to Chief Development Officer, Biologics ... -June 04, 2020 at 10:03 am EDT - …

marketscreener.com

$98
OFF

Cullinan Oncology Raises $98.5M Series B - Vcnewsdaily.com

4 weeks from now

Cullinan Oncology announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing clinical trials across its small molecule and biologics portfolio. New …

vcnewsdaily.com

$98
OFF

Cullinan Oncology Completes $98.5m Series B Financing

4 weeks from now

C ullinan Oncology, LLC announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing clinical trials across its small molecule and biologics portfolio.

pharmasources.com

$98
OFF

Cullinan Oncology Secures $98.5M - PitchBook

4 weeks from now

Jun 5, 2020 · Cullinan Oncology has raised a $98.5 million Series B from investors including MPM Capital and F2 Ventures.Based in the Boston area, the company is developing therapeutics to …

pitchbook.com

$98
OFF

Cullinan Oncology Completes $98.5 Million Series B Financing

4 weeks from now

Jon Wigginton, M.D. Joins as Chief Medical Officer Jennifer Michaelson, Ph.D. Promoted to Chief Development Officer, Biologics. CAMBRIDGE, Mass., June 4, 2020-- Cullinan Oncology, LLC …

vcaonline.com

$98
OFF

Cullinan Oncology Completes $98.5m Series B Financing

4 weeks from now

Jun 5, 2020 · New institutional investors and family offices participated in the financing alongside original commitments from founding investors MPM Capital and F2 Ventures. Following the …

pharmaceutical-business-review.com

$131
OFF

Cullinan Oncology Completes $131.2 Million Series C Financing

4 weeks from now

Dec 17, 2020 · Cullinan Oncology was formed to develop a diversified portfolio of single asset oncology opportunities through both internal and external means and to do so in a unique, …

businesswire.com

$131
OFF

Cullinan Oncology Completes $131.2 Million Series C Financing

4 weeks from now

Dec 17, 2020 · Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative …

biospace.com

$98
OFF

Cullinan Oncology Completes $98.5 Million Series B Financing

4 weeks from now

On June 4, 2020 Cullinan Oncology, LLC reported the closing of a $98.5 million Series B financing, which will be used to support ongoing clinical trials across its small molecule and …

1stoncology.com

FAQs about Cullinan Oncology Completes $98.5 Million Series B Financing Coupon?

Will Cullinan provide clinical data updates on targeted oncology programs?

Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024 ...

Who owns Cullinan oncology stock?

Top institutional investors own 0.03% of Cullinan Oncology's stock. These include SG Americas Securities LLC and Exchange Traded Concepts LLC, each owning 0.03%. ...

Should you buy Cullinan oncology (Cullinan)?

According to analysts, Cullinan Oncology has a consensus rating of Buy. The company's average rating score is 3.00, based on 4 buy ratings, no hold ratings, and no sell ratings. The consensus price target is $25.00, indicating a forecasted upside of 116.5% from its current price of $11.55. ...

What is Cullinan oncology?

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2023. ...

When is Cullinan preparing a first-in-human Phase 1 study?

Cullinan anticipates dosing the first patient in the CLN-617 first-in-human Phase 1 study by year end 2023. A poster at the 2023 SITC Annual Meeting highlighted preclinical data demonstrating the mechanism by which CLN-617 mediates a robust abscopal anti-tumor effect in preclinical models. ...

Is Cullinan responsible for any forward-looking statements included in this presentation?

Moreover, except as required by law, neither Cullinan nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this presentation. Any forward-looking statement included in this presentation speaks only as of the date on which it was made. ...